Charles B. Simone II, MD
Charles B. Simone II, MD, has been named the new Medical Director of the Maryland Proton Treatment Center (MPTC). Dr. Simone will begin work in November 2016.
As Medical Director, Dr. Simone will continue to define and implement processes ensuring that MPTC is integrated into the radiation oncology program and the University of Maryland (UM) Greenebaum Comprehensive Cancer Center, UM Medical Center/System, and UM School of Medicine.
He will also participate in development of clinical trials and research protocols; assume a leadership role within the Maryland Proton Alliance, a partnership between UM School of Medicine and MPTC; and provide expertise in refining criteria for proton therapy patient selection within the department’s clinical practice guidelines.
Prior to coming to MPTC, Dr. Simone was Co-Director of the Penn Mesothelioma and Pleural Program at the University of Pennsylvania Health System. He was also Associate Professor in the Department of Radiation Oncology at the University of Pennsylvania School of Medicine and the Thoracic Oncology Service Chief for the University of Pennsylvania Health System.
He is nationally recognized as an expert in the use of proton therapy to treat thoracic malignancies, development of clinical trial strategies, and innovative research in thoracic radiation oncology.
Dr. Simone chairs the Lung Committee of the Proton Collaborative Group and is a member of the American Society for Radiation Oncology Lung Resource Panel, the NRG Oncology Lung Cancer Committee, and the NRG Oncology Radiation Oncology Committee.
“I am very excited to work at this cutting-edge center,” said Dr. Simone. “Our goal will be to foster world-class treatment for cancers using proton therapy, as well as to further research in this area and educate outstanding researchers and clinicians.”
Dr. Simone received his medical degree from the University of Pennsylvania School of Medicine. He completed an internship at the Graduate Hospital in Philadelphia and a residency at the Radiation Oncology Branch of the National Cancer Institute, where he served as Chief Resident. ■